Home Daily Intelligence Tracker
    • Plans Blog Contact
    Alzamend Neuro Inc logo
    ALZN

    Alzamend Neuro Inc

    MaveScore 17 Low model confidence
    Last Price US$1.18 As of Jul 10, 2026
    Market Cap US$4.5m Company size context
    7D Performance 1.72% Past 7 days
    1Y Performance -61.31% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Jan 31, 2026

    162 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    14/16

    2 missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 17 Low confidence

    Stored data quality

    Freshness and coverage checks

    14/16 Current stored snapshot

    Quality

    5/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    0/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    4/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    7/15 Mixed

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    1/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Alzamend Neuro Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lith Read More

    Alzamend Neuro Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Alzamend Neuro Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Dec 12, 2024

    Quarterly result summary

    Exhibit 99.1 Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs · During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million · Stockholder equity of $3.8 million...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q filing Mar 11, 2026 SEC filing 10-Q filing Dec 09, 2025 SEC filing 10-Q filing Sep 10, 2025 SEC filing 8-K filing Jul 23, 2025 SEC filing 10-K filing Jul 22, 2025 SEC filing 10-Q filing Mar 10, 2025 SEC filing 8-K filing Dec 12, 2024 SEC filing 10-Q filing Dec 11, 2024

    Recent News



    Alzamend Neuro Mourns Loss of Director Andrew Woo
    5 hours ago
    Is ALZN stock overvalued by current metrics - July 2025 Gainers & Long-Term Safe Investment Ideas
    15 hours ago
    Is ALZN stock a safe buy before earnings - Weekly Gains Report & Risk Adjusted Buy/Sell Alerts
    15 hours ago

    Earnings Per Share

    Score 0.00/5
    Alzamend Neuro Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score -0.95/5
    Alzamend Neuro Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Alzamend Neu... ALZN US$4.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Alzamend Neuro Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Alzamend Neu... ALZN US$4.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 2.35/5
    Alzamend Neuro Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Alzamend Neu... ALZN US$4.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Alzamend Neuro Inc logo

    Alzamend Neuro Inc

    US$1.18

    US$4.5m

    1.72%

    -61.31%